Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamodikoe K Makhene

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2016
Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road AheadTawanda Gumbo, Mamodikoe K Makhene, James A Seddon
Clinical Pharmacology in Drug Development|December 30, 2020
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy VolunteersMengchun Li, George A Saviolakis, Wael El-Amin, et al.
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2016
Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road AheadTawanda Gumbo, Mamodikoe K Makhene, James A Seddon
Clinical Pharmacology in Drug Development|December 30, 2020
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy VolunteersMengchun Li, George A Saviolakis, Wael El-Amin, et al.
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 2